Co-Milling: A Successful Approach to Enhance Solubility of a Poorly Soluble Antihypertensive Drug

  • Marwa Malik Kamil Pharmaceutical Development, College of Pharmacy, Mustansiriyah University, Baghdad, Qadissiyah Express way Baghdad, Rasheed 10052, Iraq
  • Asmaa Abdelaziz Bayoumi 2. Pharmaceutics and Pharmaceutical Industry Department, College of Pharmacy, Al-Zahraa University for Women, Karbala-Baghdad Street, Holy city of Karbala, Iraq
Keywords: Olmesartan medoxomil, BCS II, Co-milling, Crospovidone; Ac-Di-Sol; HPLC.


The aim of the work was to enhance the solubilization of Olmesartan-medoxomil (OM) and formulate stable, rapidly-dissolving-tablet formulations. OM, on the other hand, is classified as Biopharmaceutics Classification System (BCS) Class II drug, which indicates that it is characterized by water-insolubility. Therefore, increasing its solubilization has the potential to boost its bioavailability. For the OM evaluation, a new HPLC technique was invented and then validated in accordance with international standards. The formulation of tablets involved co-milling with certain superdisintegrants, specifically croscarmellose sodium (Ac-Di-Sol) and crospovidone in varying percentages, followed by mixing with pH-adjusting substances such as calcium carbonate to increase solubilization in cases where the drug is soluble in alkaline. Following the evaluation of the created formulations, the optimized formulations were selected for further stability assessment. Co-milling process with crospovidone greatly improved the olmesartan release. The optimized formulations were OD11 and OD12, which exhibited fast disintegration, and the release exceeded 90% within 10 min, while the release for Olmesartan medoxomil pure standard was 9.8% after 10 min. The OD11 and OD12 were chosen for further stability assessment and revealed good stability behavior, as the study on optimized formulations revealed that the degradation was less than 5% after storage for six months at 40 °C and 75% relative humidity. Some formulations exhibited good results in terms of disintegration and release. The results of the formulations (OD11 and OD12) suggested that co-grinding with crospovidone may increase the solubilization of OM to greater than 90% after 10 minutes.


Alam, S., Bishal A & Bandyopadhyay, B. (2021). Formulation and evaluation of metformin hydrochloride sustained release matrix tablets. International Journal of Current Pharmaceutical Research. 82-88.
Alan, S., Yu, L. & BChir, M.B. in Brenner and Rector's The Kidney, 2020
Al-Shdefat, R. (2020). Solubility determination and solution thermodynamics of olmesartan medoxomil in (PEG-400 + water) cosolvent mixtures. Drug Dev Ind Pharm., 46 (12), 2098-2104.
Arun, B., Narendar, D. & Veerabrahma K. (2018). Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation, Artificial Cells, Nanomedicine, and Biotechnology, 46(1), 126-137.
Bayoumi, A.A. (2018). Enhancement of Solubility of A Poorly Soluble Antiplatelet Aggregation Drug by Cogrinding Technique. Asian J Pharm Clin. Res, 11, 340-344.
Choursiya, A. & Pandit, D. (2021). Formulation and Evaluation of Fast Dissolving Tablets of Lansoprazole by Solubility Enhancement Technique. Current Research in Pharmaceutical Sciences, 11(2), 54-64.
Dhakal, B., Thakur, J.K., Mahato, R.K., Rawat, I., Rabin, D.C. & Chhetri, R.R., et al. (2022). Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters. Scientific World Journal. 19, 9618344.
FDA (November, 2014) Expiration Dating and Stability Testing for Human Drug Products. Retrieved on April 4, 2022 from
González, R., Peña, M.Á. & Torrado, G. (2022). Formulation and Evaluation of Olmesartan Medoxomil Tablets. Compounds, 2 (4), 334-352.
Hari, K., Rajeswari, S. & Ramanamurthy, V.K. (2018). Preparation and Evaluation of Orally Disintegrating Tablets of Drotaverine Hydrochloride Using Sublimation Technique. Int J Pharm Pharm Sci, 10, 85-95.
ICH. International Conference on Harmonization, Validation of Analytical Procedures: Text and Methodology, Q 2 (R1). ICH, 2005.
ICH Q1A (R2) Stability testing of new drug substances and drug products - Scientific guideline (2003)
Karuna, D.S., Sowjanya, L., Ubaidulla, U., Rathnam, G. (2014). Formulation and Evaluation of Triple Drug Combination of Olmesartan Medoximal, Amlodipine Besylate and Hydrochlorothiazide Tablets, International Journal of Advanced Pharmaceutics, 4(2),146-153.
Kassem, A.M., Mohamed, I.M. & Mohamed, A.A. (2016). Development and validation of a stability indicating assay for azilsartan kamedoxomil in solid dosage forms. Int. J. of Adv. Res, 4, 1630-1639.
Koike, H., Konse, T., Sada, T., Ikeda, T., Hyogo, A., Hinman, D., Saito, H. & Yanagisawa, H. (2003). Annual Report Sankyo Research Laboratories, 55: 1-91.
Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press (2011).
Rahane, R.D. & Rachh, P. (2018). A review on fast dissolving tablet. Journal of Drug Delivery and Therapeutics. 8, 50-55.
Rahi, F.A., Mohammed, M.S & Fayyadh, M.S. (2021). Linagliptin and gliclazide di-loaded extended-release nanoparticles: formulation and evaluation. Wiad Lek, 74 (9 cz 2):2315-2322.
Hidayati, N., Sulaiman, T & Nurhaini, R. (2020). Optimization formula of fast disintegrating tablets Ketoprofen β-cyclodextrin inclusion complex with sodium starch glycolate and crospovidone as the superdisintegrants. J Phys Conf Ser. 1517, 012047.
Huang, Y., Cao, L., Parakhonskiy, B.V. & Skirtach, A.G. (2022). Hard, Soft, and Hard-and-Soft Drug Delivery Carriers Based on CaCO3 and Alginate Biomaterials: Synthesis, Properties, Pharmaceutical Applications. Pharmaceutics, 14, 909.
Saab, M. & Mehanna, M.M. (2019). Disintegration time of orally dissolving films: various methodologies and in-vitro/in-vivo correlation. Pharmazie, 74(4), 227-230.
Sumaiyah, S., Mentari, J. & Suryanto S. (2019). The Effect of Crospovidone on the Dissolution Profile of Amlodipine Besylate from Fast Orally Dissolving Film. Open Access Maced J Med Sci., 7, 3811-3815.
The Pharmacopoeia of United States of America", 43th Ed., National Formulary 38, Mack publishing Co. Easton, vol. 2, Electronic version (2019).
World Health Organization (1996) Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms. Retrieved on April 4, 2022 from
Vaughan, A.S., Coronado, F., Casper, M., Loustalot, F. & Wright, J.S. (2022). County-Level Trends in Hypertension-Related Cardiovascular Disease Mortality-United States, 2000 to 2019external icon. J Am Heart Assoc, 11(7), e024785.
How to Cite
Kamil, M. M., & Bayoumi, A. A. (2023). Co-Milling: A Successful Approach to Enhance Solubility of a Poorly Soluble Antihypertensive Drug . Indonesian Journal of Pharmacy, 34(3), 439–449.
Research Article